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Conclusion: The antimicrobial activity of the extract could be
enhanced if the components are puriﬁed. This plant therefore holds a
promising potential source of new drug for treating infections caused
by these clinical pathogens.
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Background: Fast breathing pneumonia or isolated tachypnea
in children, is presumed to be mostly viral in origin. WHO guide-
lines recommend 3 days of amoxicillin therapy for all childrenwith
fast breathing pneumonia in resource limited settings. The recom-
mendations have arisen largely out of hospital studies where the
spectrum of disease is more severe. High quality clinical trial evi-
dence to challenge or support the continued use of antibiotics, in
low-resource community settings is lacking.
Methods & Materials: A community based randomized double
blinded placebo-controlled non-inferiority trial is being conducted
at primary healthcare centres located in two low income squat-
ter settlements of Karachi, Pakistan. Children aged 2-59 months
with WHO deﬁned fast breathing pneumonia are included if they
have no danger signs, SaO2 ≥ 90% on pulse oximetry, absence
of use of antibiotics in last 48 hours, no bulging fontanels, pedal
edema, asthma, tuberculosis or congenital heart disease. Children
are being randomized to receive either 3 days of oral Amoxicillin
(standard) or matching placebo (intervention), with 1215 children
to be enrolled in each arm. Primary outcome is the difference in
treatment failure rates between the two groups, deﬁned as a new
clinical sign based on preset deﬁnitions indicating illness progres-
sion or mortality on day 0, 1, 2 or 3 of therapy.
Results: FromSeptember 2014 till August 2015, a total of 19,363
children were triaged. Among these, 11,161 (58%) presented with
cough or difﬁculty in breathing. 2,216 (20%) met the inclusion cri-
teria i.e. have history of cough for less than two weeks and have
tachypnea. About 40% of all fast breathing under 5 years occurs
in babies 2-11 months of age. Of these children with fast breath-
ing, 1056 children have been enrolled so far. The overall treatment
failure is 3% and no mortality.
Conclusion: The overall rates of treatment failure and relapse in
fast breathing pneumonia are low. The trial results will strengthen
the evidence to support or refute the use of antibiotics in WHO-
IMCI management of pneumonia. Findings will be generalizable
to resource limited settings with low HIV and malaria prevalence
andHib andPneumococcal vaccines in their national immunization
plan.
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Background: A renewed interest in the usage of polymyxins has
been observed, as they are the only treatment option left for mul-
tidrug resistant (MDR) and pan-drug resistant (PDR) pathogens like
Acinetobacter baumannii. However, knowledge of the pharmacoki-
netics (PK) and pharmacodynamics (PD) of polymyxins is limited,
resulting in inappropriate dosing, potential toxicity and develop-
ment of resistance. We planned to conduct this prospective PK-PD
studyof intravenously administered colistin in Indianpatientswith
MDR Gram-negative infections to estimate the levels of both total
and free colistin.
Methods & Materials: This was a prospective PK-PD study
of intravenously administered colistin in ten patients with MDR
Gram-negative infections. The recommended systemic dose of pro-
drug, colistin methanesulfonate (CMS) was given as 4–6 mg/kg per
day as a short-term infusion (for 1 hour) or 1–2 million IU/day
in three divided doses (12,500 IU/1mg of CMS). Highly sensitive
UHPLC-MS/SRM method was developed and validated to quantify
free and total colistin from human sera. Correlation between the
predictor variables like AUC/MIC ratiowas performed usingGraph-
PadInstat ver. 6 for Mac version 10.10.1 (GraphPad Software, San
Diego CA: www.graphpad.com).
Results: The area under the plasma concentration-versus-time
curve over 8 hrs (AUC0 – 8) for free and total colistin ranged after 5th
dose from28.2 to126mg*Y¨h/liter and25.8 to404.9mg*Y¨h/l respec-
tively. All the follow up blood cultures were sterile and majority of
the patients survived.
AUC (0-8) for free and total colistin after 1st(A, C) and 5th
doses (B,D) in 10 patients
Conclusion: This is the ﬁrst Indian study where free colistin
levels were also estimated. The desired colistin levels to be effec-
tive without giving the loading dose were achieved in these Indian
